Aclaris Therapeutics Reports 37% Revenue Growth but Increased Net Loss in Q1 2026

Aclaris Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing total revenues of $1.996 million, a 37% increase from $1.455 million in the same period last year. The growth in revenue was primarily driven by a rise in licensing income, which increased to $1.459 million from $1.010 million, alongside a modest increase in contract research revenue from $445,000 to $537,000. Despite this revenue growth, the company reported a net loss of $19.824 million, compared to a loss of $15.085 million in the first quarter of 2025, reflecting ongoing investments in research and development.

Total expenses for the quarter rose to $24.188 million, up from $19.539 million in the prior year, largely due to increased research and development costs, which climbed to $15.657 million from $11.584 million. General and administrative expenses also saw a slight increase, totaling $6.743 million compared to $6.139 million in the previous year. The company’s accumulated deficit reached $987.608 million as of March 31, 2026, highlighting the ongoing financial challenges faced by the firm as it continues to invest heavily in its product pipeline.

Aclaris has made significant strides in its operational activities, including the advancement of its clinical-stage product candidates. The company is focusing on several investigational therapies for immuno-inflammatory diseases, including bosakitug, ATI-2138, and ATI-052. The company has initiated various clinical trials, including a Phase 2 trial for bosakitug in atopic dermatitis, with top-line data expected in the fourth quarter of 2026. Additionally, Aclaris has expanded its workforce, contributing to increased personnel costs, which were noted as a factor in the rise of general and administrative expenses.

In terms of liquidity, Aclaris reported cash, cash equivalents, and marketable securities totaling $190.8 million as of March 31, 2026, an increase from $160.460 million at the end of 2025. The company raised $57.8 million through the issuance of common stock under an at-the-market sales agreement in March 2026, which bolstered its financial position. However, Aclaris cautioned that it will require additional capital to support ongoing development activities and operational expenses, as it anticipates continued net losses in the near term.

Looking ahead, Aclaris remains focused on advancing its product candidates through clinical development while exploring potential partnerships to enhance its market position. The company acknowledges the challenges posed by macroeconomic conditions, including inflation and geopolitical tensions, which could impact its ability to raise additional funds. Aclaris is committed to executing its long-term strategy, but the success of its initiatives will depend on the outcomes of its clinical trials and the ability to secure further financing.